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Abstract
Aim To explore the metabolic phenotype of obesity-related secondary hypogonadism (SH) in men pre-replacement and
post-replacement therapy with long-acting intramuscular (IM) testosterone undecanoate (TU).
Methods A prospective observational pilot study on metabolic effects of TU IM in male obesity-related SH (hypogonadal
[HG] group, n= 13), including baseline comparisons with controls (eugonadal [EG] group, n= 15). Half the subjects (n= 7
in each group) had type 2 diabetes mellitus (T2D). Baseline metabolic assessment on Human Metabolism Research Unit:
fasting blood samples; BodPod (body composition), and; whole-body indirect calorimetry. The HG group was treated with
TU IM therapy for 6–29 months (mean 14.8-months [SD 8.7]), and assessment at the Human Metabolism Research Unit
repeated. T-test comparisons were performed between baseline and follow-up data (HG group), and between baseline data
(HG and EG groups). Data reported as mean (SD).
Results Overall, TU IM therapy resulted in a statistically signiﬁcant improvement in HbA1C (9 mmol/mol, P= 0.03), with
52% improvement in HOMA%B. Improvement in glycaemic control was driven by the HG subgroup with T2D, with 18
mmol/mol [P= 0.02] improvement in HbA1C. Following TU IM therapy, there was a statistically signiﬁcant reduction in fat
mass (3.5 Kg, P= 0.03) and increase in lean body mass (2.9 kg, P= 0.03). Lipid proﬁles and energy expenditure were
unchanged following TU IM therapy. Comparisons between baseline data for HG and EG groups were equivalent apart from
differences in testosterone, SHBG and basal metabolic rate (BMR).
Conclusion In men with obesity-related SH (including a subgroup with T2D), TU IM therapy improved glycaemic control,
beta cell function, and body composition.
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Abbreviations
AHI Apnoea-hypopnoea index
ALT Alanine transaminase
BMI Body Mass Index
BMR Basal metabolic rate
DHT Dihydrotestosterone
DM Diabetes mellitus
EE Energy expenditure
EG Eugonadal
FAI Free androgen index
FSH Follicle stimulating hormone
GSIS Glucose-stimulated insulin secretion
Hb Haemoglobin
Hct Haematocrit
HG Hypogonadal
HMRU Human Metabolism Research Unit
HOMA %
B
Homeostasis model assessment of beta-cell
function
HOMA2
IR
Homeostasis model assessment of insulin
resistance
IM Intramuscular
LH Luteinizing hormone
NS Non-signiﬁcant
OSA Obstructive sleep apnoea
PSA Prostate speciﬁc antigen
SD Standard deviation
SH Secondary hypogonadism
SHBG Sex hormone binding globulin
TEF Thermic effect of food
T2D Type 2 diabetes mellitus
TRT Testosterone replacement therapy
TU Testosterone undecanoate
UHCW University Hospitals Coventry and
Warwickshire
WBC Whole-body calorimeter
WISDEM Warwickshire Institute for the Study of Dia-
betes, Endocrinology and Metabolism
Introduction
Weight-gain in men, with resultant obesity is commonly
associated with the development of obesity-related sec-
ondary hypogonadism (SH) [1, 2]. There are complex
interlinks between the development of obesity-related SH
and other metabolic dysfunctions including impaired glu-
cose tolerance, type 2 diabetes mellitus (T2D), hyperten-
sion, dyslipidaemia, and obstructive sleep apnoea (OSA).
Pathogenic factors are complex and multidirectional, and
likely to include suppressive effects of oestradiol on the
hypothalamo-pituitary gonadotrophic control of testicular
testosterone production (and spermatogenesis) through
increased aromatization of testosterone within visceral adi-
pocytes [1]. Other mechanisms are likely to involve leptin,
pro-inﬂammatory cytokines, and changes in body compo-
sition that result in the development of testosterone deﬁ-
ciency [1]. Obesity-related SH is a common condition and
in one prospective study on 100 Spanish men with
moderate-to-severe obesity, prevalence of obesity-related
SH was reported as 45% [3]. In a further study from the
Netherlands on 160 obese men, obesity-related SH (based
on total testosterone levels) was present in 57.5% of the
sample [4]. It should be noted, however, that levels of
plasma testosterone are reduced spuriously by non-fasting
status [5]. There is some controversy therefore regarding the
true prevalence of obesity-related SH, and future studies in
this ﬁeld should avoid use of non-fasting measurements of
plasma testosterone levels.
It is well-established that gonadotrophin-mediated
reductions in plasma testosterone levels are observed in
men with all forms of chronic disease or acute illness [6].
Furthermore, a general lack of awareness amongst health-
care professionals regarding male obesity-related SH as a
clinical entity, and its appropriate screening and manage-
ment remain contentious. It is likely that many cases of
male obesity-related SH remain undiagnosed and untreated.
Furthermore, the pathogenic mechanisms that underlie
development of obesity-related SH in men, its association
with metabolic dysfunction and the effects of testosterone
replacement therapy (TRT) remain incompletely
understood.
Improvement of insulin sensitivity through administra-
tion of TRT in hypogonadal men has attracted less con-
troversy, with a number of published studies conﬁrming
such an effect [7]. In one study, TRT was shown to improve
insulin sensitivity in subjects with T2D, demonstrated
through improved glucose disposal rate during hyper-
insulinaemic euglycaemic clamp [8]. A further study on
androgel in men with partial androgen deﬁciency of aging
showed reduction of visceral fat and improvement of insulin
resistance [9]. These observations have been corroborated
by data from animal studies that have also shown beneﬁts of
TRT on components of glucose uptake [10]. Furthermore,
in vitro studies on the effects of testosterone in human
subcutaneous adipocytes have shown increased expression
of Glucose transporter type 4 (GLUT4) and Protein Kinase
B (Akt), which in turn would be expected to facilitate
enhanced glucose uptake and insulin sensitivity [8]. There
are few published studies, however, that report on the
effects of testosterone on beta cell insulin release in hypo-
gonadal men. Of note, there were no changes in HOMA %B
demonstrated with TRT in hypogonadal men in the TIMES
2 study [11].
The primary outcome of this study was change in
HbA1C in obese hypogonadal men following testosterone
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undecanoate intramuscular (TU IM) therapy. Secondary
outcomes following TU IM therapy in this group included
changes in measures of insulin sensitivity and beta cell
functioning (HOMA2 IR and HOMA %B, respectively),
metabolic proﬁle, body fat and lean mass, and fasting lipid
proﬁle. A further secondary outcome was a (baseline)
metabolic comparison between obese hypogonadal and
obese eugonadal men. The study reported is observational
rather than a clinical trial. All administration of TU IM
therapy was based on clinical need. To our knowledge, our
study includes the ﬁrst detailed assessment of metabolic rate
through use of indirect calorimetry in a whole-body
calorimeter (WBC) in men with obesity-related SH. This
pilot study has two main components: (i) a longitudinal
observational study on the metabolic effects of TU IM
therapy in men with obesity-related SH, and; (ii) baseline
comparisons of metabolic data from hypogonadal and
eugonadal obese men. This report will be structured
accordingly.
Materials and methods
Subjects
Adult, obese (BMI > 30 kg m−2) male subjects (n= 28)
were recruited from the obesity clinic at the Warwickshire
Institute for the Study of Diabetes, Endocrinology and
Metabolism (WISDEM) Centre, University Hospitals
Coventry and Warwickshire (UHCW) NHS Trust. The
subjects were divided into two main groups. The ﬁrst
hypogonadal (“HG”) group (n= 13) included those with a
conﬁrmed diagnosis of obesity-related SH. This diagnosis
was based on conﬁrmed biochemical hypogonadism (9 am
fasting serum testosterone <8 nmol/l on at least two
separate days), with normal range levels of gonadotrophins
LH and FSH. There were also clinical features of hypo-
gonadism in all subjects within the HG group including
either low libido and/or erectile dysfunction. In the HG
group, other secondary causes of hypogonadism (such as
prolactinoma, haemochromatosis, and congenital forms
i.e., Kallman’s syndrome and compression effect from a
pituitary mass) had been excluded. Furthermore, there
were no other endocrine abnormalities. Within the HG
group, seven subjects also had a conﬁrmed diagnosis of
T2D. Following baseline assessment on the Human
Metabolism Reseach Unit (HMRU), all subjects in the HG
group were commenced on TU 1000 mg injections (TU,
Nebido®, Bayer AG, Germany) IM therapy for the dura-
tion of the study. TU IM was administered at 12-weekly
intervals (with the second IM injection administered at 6-
weeks following the ﬁrst injection) as per prescribing
guidelines.
The second eugonadal (“EG”) group (n= 15) included
those with conﬁrmed biochemical eugonadism with 9 am
serum testosterone levels >10 nmol/l, normal-range gona-
dotrophins and absence of clinical features of hypogonad-
ism. Within the EG group, a subgroup (n= 7) had a
conﬁrmed diagnosis of T2D. The duration of T2D and
glycaemic therapies (for the subgroup of subjects with T2D
in both the HG and EG groups) varied between 2 and 10
years. There were no exclusions regarding glycaemic
therapies for those subjects with T2D, nor for statin or
ﬁbrate therapies. Only baseline assessment of the EG group
on the HMRU was performed. Follow-up analyses were
therefore restricted to the HG group following administra-
tion of TU IM therapy. The purpose of the EG assessment
was to provide comparative data for the baseline metabolic
assessment of the HG group.
Exclusion criteria included prior bariatric surgery,
current/prior use of weight-loss therapies or any other
treatment with androgenic or antiestrogenic properties.
Use of prior TRT was a further exclusion criterion.
None of the subjects had any existing or prior diagnosis
of OSA or renal impairment at enrollment into the study.
All clinical investigations were conducted in accordance
with the guidelines in the Declaration of Helsinki.
All subjects provided fully informed written consent prior
to enrollment into the study, and a local Research
Ethics Committee in the United Kingdom approved the
study.
Testosterone replacement therapy
Following baseline assessment on the HMRU, all hypogo-
nadal subjects were initiated on TRT. For all subjects, the
replacement used was TU IM therapy. The dosing schedule,
as per prescribing guidelines, was as follows: Following an
initial IM injection of TU 1 g, the second injection was
administered at 6-weeks, and subsequent injections at 12-
weekly intervals. TU IM injections were administered by
the patient’s practice nurse based at their primary care set-
ting. None of the subjects receiving TU IM therapy required
venesection.
Anthropometric, indirect calorimetric, energy
balance, and sleep-based evaluations
All metabolic studies were conducted on the HMRU,
described previously [12]. Subjects arrived at the HMRU
for each of their assessments at 9 am in a fasting state
(having fasted for 12-h prior to the study). Furthermore,
subjects were advised to maintain a stable and isocaloric
diet for 72 h before each of their visits (using a three day
food questionnaire), whilst strenuous physical activity and
caffeine ingestion were avoided for at least 24-h prior to
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each metabolic assessment on the HMRU. Following arrival
at the HMRU and a fasting blood sample, each subject
underwent anthropometric assessment of overall body fat
and lean mass using a BodPod. The technique of body
composition analysis from a BodPod is based on air dis-
placement plethysmography (Cosmed Inc., USA) [13].
Body weight and height were measured.
Following anthropometric measurements, each subject
entered a WBC, located at the HMRU at 1000 h, and was
requested to lie on the bed for the ﬁrst 30 min to allow for
equilibration within the WBC. A macronutrient balanced
breakfast meal was served at 1030 h, standard lunch at
1300 h, standard evening meal at 1800 h and standard
snack at 2200 h. Subjects were requested to sleep between
2300 and 0730 h, and exited the WBC at 0800 h. The
duration of each WBC study was therefore 22 h. Whilst
inside the WBC, subjects were requested to avoid any
physical activity. During each WBC study, minute-by-
minute samples of air entering and leaving the WBC were
measured accurately for levels of CO2 and O2. From these
measurements of CO2 and O2, energy expenditure was
calculated, providing a continous assessment of metabolic
rate (Kcal/min) for the duration of each WBC study.
Energy expenditure (EE) was calculated using Weir’s
formula [14]: EE (Kcal)= [3.941×O2 consumed (L)]+
[1.106× CO2 produced (L)]. Further details regarding the
WBC have been described previously [12]. During each
WBC assessment, relative humidity (57 ± 5%) and ther-
moneutral temperature (24 ± 0.5 °C) were tightly con-
trolled. The timings and procedures for each study at the
HMRU were identical for all metabolic assessments
(including all baseline and all follow-up studies), to limit
any potential for confounding effects. All subjects
(including the HG and EG groups) underwent a baseline
metabolic assessment at the HMRU. All those subjects in
the HG group underwent a further follow-up metabolic
assessment at the HMRU following TU IM replacement
therapy for at least a 6-month period.
For each assessment at the HMRU, basal metabolic rate
(BMR) was calculated from minute-by-minute EE during
the 1-h nocturnal period (between 0500 h and 0559 h) when
subjects were asleep. Thermic effect of food (TEF) was
calculated from EE readings during the 4-hour period fol-
lowing the standard lunch (1300–1659 h) (EE–BMR).
Finally, overall metabolic rate (21-h) whilst inside the WBC
was calculated from the EE readings between 1030 and
0730 h for each WBC assessment. Sleep studies using an
Alice PDX portable sleep machine (generously provided by
Phillips Respironics) were performed on a subgroup of the
subjects whilst sleeping inside the WBC, based on initial
scoring on the Epworth test (sleep assessment conducted if
a subject had a score of at least 10).
Biochemical evaluation
Prior to each metabolic assessment at the HMRU, fasting
blood samples were taken. Following immediate spinning
of each sample in a centrifuge, serum was extracted and
analyzed for lipid proﬁle (total cholesterol, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, and triglycerides), HbA1C, glucose,
insulin, testosterone, estradiol, prostate speciﬁc antigen
(PSA), sex hormone binding globulin (SHBG), haemoglo-
bin (Hb), and alanine transaminase (ALT). Serum insulin
was measured with a chemiluminescent assay (DPC
immulite 2500 machine). Glucose was measured using a
hexokinase assay (ADVIA 2400 analyser). Serum testos-
terone and SHBG were measured using chemiluminescent
assays (Immulite 2000 analyser). The normal reference
range for testosterone in men using this assay was 8.6–29
nmol/l. Adiponectin and leptin were measured using a
Sandwich ELISA (in vitro enzyme-linked immunosorbent)
assay (Sigma). Intra-assay coefﬁcient of variation for all
assays used was <7%. Values for Homeostasis Model
Assessment of Insulin Resistance (HOMA2 IR) and
Homeostasis Model Assessment of Beta-cell function
(HOMA %B) were calculated from paired measures of
fasting plasma glucose and insulin levels for each subject at
each of their visits at the HMRU, using the Oxford Diabetes
Trials Unit HOMA2 calculator (https://www.dtu.ox.ac.uk/
homacalculator/). Subjects on insulin therapy were exclu-
ded from HOMA analyses. Given the importance of con-
sidering levels of SHBG when assessing male
androgenicity, we also calculated free (bioavailable) tes-
tosterone levels using the formula, free androgen index
(FAI)= 100× (total testosterone/SHBG), with units of
testosterone and SHBG in nmol/l.
Statistical analyses and power calculation
Statistical analyses were conducted in SPSS (version 22
Windows; SPSS Inc., Chicago, IL). Data for most analytes
(including testosterone) were approximately normally-
distributed. Paired two-tailed t-tests were used for compar-
isons between baseline and follow-up data (following
treatment with TU IM replacement therapy) for each of the
subjects in the HG group. For these analyses, each subject
acted as their own control thereby limiting confounding.
Independent sample t-tests were used for comparisons
between baseline data from the HG and EG groups. We had
>80% power to detect a between-group difference in
HbA1C exceeding 100% of a standard deviation (SD)
(alpha= 0.05). A P-value <0.05 was considered signiﬁcant.
Data are shown as mean and standard deviation (SD) unless
otherwise stated.
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Results
Longitudinal observation of the metabolic effects of
TU IM therapy: paired-sample t-test comparisons
between baseline and follow-up data in the HG
group
In the hypogonadal (HG) group (n= 13), subjects were
treated with TU IM therapy (TRT) for at least 6-months
between baseline and follow-up metabolic assessments at
the HMRU (mean [SD] duration of TU IM therapy
14.8 months [8.7]). The maximum duration of TU IM
therapy between metabolic assessments was 29-months.
Given the dosing schedule for TU IM therapy, all HG
subjects had received at least four injections of TU at their
follow-up study, with a mean number of six injections.
Follow-up metabolic assessments for HG subjects were
executed between 10 and 12-weeks following the last TU
IM injection.
As expected, there was a signiﬁcant improvement in
serum trough testosterone levels between baseline and
follow-up assessments (mean serum trough testosterone
[SD] 6.7 nmol/l [5.9] vs. 15.2 nmol/l [6.4], P= 0.046; for
baseline and follow-up assessments at the HMRU, respec-
tively). There was also a signiﬁcant improvement in FAI
following TU IM therapy (mean FAI [SD] 28.3 [12.7] vs.
60.8 [35.5], P= 0.01; for baseline and follow-up assess-
ments at the HMRU, respectively). TRT resulted in statis-
tically signiﬁcant improvements in anthropometric
measures of body composition, with (mean) reduction in fat
mass of 3.5 kg (P= 0.03) and (mean) increase in lean body
mass of 2.9 kg (P= 0.03). There was also a 2.8% (P=
0.03) reduction in body fat percentage following TRT (data
shown in Table 1).
Most of the HG group had a conﬁrmed diagnosis of T2D
(n= 7), with the remainder euglycaemic (n= 6). There was
a statistically signiﬁcant improvement in glycaemic control
amongst the whole HG group following TRT, with (mean)
improvement in HbA1C of 9 mmol/mol (P= 0.03).
Although there was a trend for HOMA IR reduction with
TRT therapy (HOMA IR at baseline versus follow-up, 5.5
vs. 4.5, respectively, P= 0.32), this did not reach statistical
signiﬁcance. There was however, a signiﬁcant improvement
in beta-cell function following TRT (mean HOMA %B
improved by 52%), despite only non-signiﬁcant reductions
in fasting glucose and insulin levels (Table 1). Comparisons
between baseline and follow-up HMRU assessments of
overall metabolic rate and TEF showed no signiﬁcant
changes with TRT. Although there was a numerical increase
in BMR following TRT, this also failed to reach sig-
niﬁcance (Table 1). There were no changes in lipid para-
meters following TRT. There was a signiﬁcant (mean) small
increase in PSA by 0.3 following TRT, although PSA
remained well within the normal range in all subjects.
Following TRT, serum estradiol level doubled (P= 0.04)
and there was a signiﬁcant increase in SHBG by 3.7 nmol/l
(P= 0.003). (Data are shown in Table 1).
Subgroup analyses revealed that the improvements in
HbA1C with TRT for those subjects in the HG group were
conﬁned to the subgroup with an established diagnosis of
T2D (n= 7). Within this subgroup, baseline and follow-up
(mean) HbA1C levels were 70 [SD 9.2] vs. 52 mmol/mol
[SD 4.0], P= 0.023, respectively. There was no signiﬁcant
change in HbA1C for the euglycaemic HG subgroup (n=
6), with baseline and follow-up (mean) HbA1C levels 42.6
[SD 3.9] vs. 41.2 mmol/mol [SD 4.3], P=NS respectively.
Baseline (independent t-test) comparisons of
metabolic data between the HG and EG groups
Data from baseline measurements in the HG group were
compared with those from a control eugonadal (EG) group
(n= 15). Within the EG group, a subgroup (n= 7) had a
conﬁrmed diagnosis of T2D, and the remainder (n= 8) had
conﬁrmed euglycaemia, and no present or past history of
DM. As per deﬁnition, there was a statistically signiﬁcant
difference in (mean) baseline serum testosterone levels
between the HG and EG groups (baseline serum testoster-
one 6.7 nmol/l [SD 5.9] vs. 14.2 nmol/l [SD 5.0], P= 0.036
respectively). There was also a signiﬁcant difference in
baseline serum SHBG levels between the groups (baseline
serum SHBG 21.3 nmol/l [SD 6.9] vs. 37.8 nmol/l [SD
19.6], P= 0.010 for HG and EG groups, respectively).
Interestingly, despite there being similar lean mass at
baseline between the HG and EG groups, the HG group had
a statistically greater BMR at baseline than the EG group
(92.6 vs. 79.9 Kcal, respectively, P= 0.040, Table 2). All
other baseline comparisons between the HG and EG groups
were statistically equivalent (data shown in Table 2).
Sleep data
Overall, polysomnography (using a portable Alice PDX
sleep machine) was assessed in 13 subjects at baseline on
the basis of an Epworth score of at least 10 (including those
from the HG [n= 6]) and EG [n= 7] groups). Of these,
there were 9 (32% of the recruited subjects overall) from the
HG (n= 5) and EG (n= 4) groups who had newly-
diagnosed and treatable OSA (deﬁned by an apnoea-
hypopnoea index [AHI] > 15/h). Of these, 4 (14% of the
recruited subjects overall; two from each group) had severe
OSA (AHI > 30/hour). Sleep studies were not repeated
following TRT. The nine subjects who were diagnosed with
treatable OSA were treated with continuous positive air-
ways pressure therapy. Of these nine subjects, ﬁve also had
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T2D (three within the HG group and two within the EG
group).
Changes to glycaemic therapies in the HG subgroup
with T2D during treatment with TRT
In the HG subgroup with T2D (n= 7), baseline glycaemic
management was as follows: lifestyle (n= 1); metformin
monotherapy (n= 2); dual therapy with metformin and
liraglutide (n= 1); dual therapy with meformin and sita-
gliptin (n= 1); quadruple therapy with metformin, piogli-
tazone, gliclazide and liraglutide (n= 1), and; triple therapy
with metformin, liraglutide, lantus and novorapid (n= 1).
During TRT and prior to the follow-up visits, glycaemic
therapies remained unchanged in four subjects. In one
subject, dual therapy with metformin and liraglutide was
intensiﬁed by the addition of levemir (12 units od). In one
subject, dual therapy with metformin and sitagliptin had
been changed to metformin and liraglutide. In one subject,
quadruple therapy with metformin, pioglitazone, gliclazide
and liraglutide was changed to metformin, pioglitazone,
lantus (20 units od) and canagliﬂozin. Details of glycaemic
therapies for the HG subgroup with T2D are shown in
Table 3.
Discussion
In this well-phenotyped study on the metabolic effects of
TU IM therapy in obese men with secondary hypogonad-
ism, we demonstrate signiﬁcant improvements in glycaemic
control (likely mediated at least in part through improved
beta-cell function [HOMA %B]) and favorable changes in
body composition, consistent with several other studies
reported with TRT [11, 15–17]. With TRT, there was also a
statistically signiﬁcant improvement in SHBG (known to
Table 1 Comparison of
anthropometric, biochemical and
metabolic data between
assessments performed at
baseline and following treatment
with TU IM testosterone
replacement therapy (paired
sample t-tests; bold p-values
indicate statistical signiﬁcance)
Phenotype Baseline HG group mean
(SD) (n= 13)
Follow-up HG group
mean (SD) (n= 13)
Paired-sample t-test
comparison
BMI (kg m−2) 38.5 (6.0) 38.0 (5.5) 0.18
Age (years) 49.4 (8.8) N/A N/A
Body weight (kg) 120.9 (18.6) 119.5 (16.3) 0.26
Fat mass (kg) 51.2 (15.8) 47.7 (16.1) 0.033
Lean mass (kg) 67.9 (7.0) 70.8 (6.6) 0.028
Body fat (%) 42.2 (7.1) 39.4 (8.8) 0.030
BMR (Kcal 5–6 am) 92.6 (14.7) 97.0 (13.4) 0.24
Metabolic rate 21 h (Kcal) 2316 (353) 2321 (328) 0.90
Thermic effect of food
(Kcal)
495 (80) 498 (73) 0.78
Hb (g/dl) 15.2 (1.1) 15.7 (1.1) 0.16
ALT (U/l) 36 (15) 29 (13) 0.11
HbA1C (mmol/mol) 56 (16) 47 (7) 0.028
Fasting glucose (mmol/l) 9.3 (3.3) 6.8 (1.9) 0.10
Fasting insulin (pmol/l) 270 (188) 240 (133) 0.51
HOMA2 IR 5.5 (3.8) 4.5 (2.4) 0.32
HOMA %B 108 (46) 160 (78) 0.05
Total cholesterol (mmol/l) 4.1 (1.0) 4.0 (0.8) 0.74
HDL cholesterol (mmol/l) 1.1 (0.1) 1.1 (0.2) 0.19
LDL cholesterol (mmol/l) 2.4 (1.0) 2.2 (0.8) 0.45
Triglycerides (mmol/l) 1.7 (0.7) 1.8 (0.9) 0.61
Adiponectin (pg/ml) 1520 (461) 1489 (320) 0.87
Leptin (pg/ml) 164 (99) 144 (99) 0.31
Estradiol (pmol/l) 97 (54) 194 (75) 0.042
PSA (ng/ml) 0.8 (0.5) 1.1 (0.7) 0.022
Testosterone (nmol/l) 6.7 (5.9) 15.2 (6.4) 0.046
SHBG (nmol/l) 21.3 (6.9) 25.0 (7.5) 0.003
Haematocrit (%) 45.5 (3.4) 47.2 (3.3) 0.19
Haemoglobin (g/dl) 14.8 (1.3) 15.3 (1.2) 0.16
Free androgen index 28.3 (12.7) 60.8 (35.5) 0.01
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correlate with insulin sensitivity and BMI in obese men)
[18, 19]. The observed signiﬁcant increase in serum estra-
diol levels following TU IM therapy in the HG group likely
reﬂects aromatization of exogenously-administered testos-
terone within adipocytes. The lack of signiﬁcant changes in
metabolic rate and fasting lipid proﬁles with TU IM therapy
may be explained by lack of power, the relatively small
changes in body composition following TU IM therapy, and
possible changes in dietary and lifestyle factors (such as
propensity for exercise) amongst hypogonadal subjects
during TU IM therapy. The signiﬁcant difference in base-
line BMR between the HG and EG groups is harder to
explain, given the similarity of lean mass between the two
groups. Given the apparent lack of effect of TRT on
metabolic rate in the HG group, it is difﬁcult to attribute the
difference in baseline BMR between the HG and EG groups
to differences in testosterone. It remains possible that dif-
ferences in other features between the two groups that were
not measured (such as physical ﬁtness for example) may, at
least partly explain this difference, although this is purely
speculative.
In one of the largest studies on TRT in hypogonadal men
published to date (TIMES2 study), Jones and Colleagues
reported a 16.4% improvement in HOMA IR following
administration of transdermal 2% testosterone gel over 12-
months in 220 hypogonadal men with T2D and/or meta-
bolic syndrome [11]. In the subgroup with T2D, there was
an improvement in HbA1C and in total and LDL cholesterol
Table 2 Comparison of
anthropometric, biochemical,
and metabolic data between
assessments performed at
baseline for hypogonadal (HG)
and eugonadal (EG) groups
(independent sample t-tests;
bold p-values indicate statistical
signiﬁcance)
Phenotype Baseline HG group
mean (SD) (n= 13)
Baseline EG group
mean (SD) (n= 15)
Independent-sample t-test
comparison
BMI (Kg m−2) 38.5 (6.0) 36.6 (5.5) 0.47
Age (years) 49.4 (8.8) 50.4 (12.1) 0.81
Body weight (kg) 120.9 (18.6) 110.5 (18.2) 0.27
Fat mass (kg) 51.2 (15.8) 43.9 (17.6) 0.34
Lean mass (kg) 67.9 (7.0) 65.0 (6.1) 0.33
Body fat (%) 42.2 (7.1) 39.1 (9.7) 0.46
BMR (Kcal 5–6 am) 92.6 (14.7) 79.9 (10.8) 0.040
Metabolic rate 21 h (Kcal) 2316 (353) 2065 (287) 0.12
Thermic effect of food
(Kcal)
495 (80) 441 (65) 0.17
ALT (U/l) 36 (15) 28 (25) 0.30
HbA1C (mmol/mol) 56 (16) 49.2 (21.5) 0.33
Fasting glucose (mmol/l) 9.3 (3.3) 6.7 (1.0) 0.11
Fasting Insulin (pmol/l) 270 (188) 141 (74) 0.09
HOMA2 IR 5.5 (3.8) 2.7 (1.4) 0.07
HOMA %B 108 (46) 108 (49) 0.65
Total cholesterol (mmol/l) 4.1 (1.0) 4.2 (0.8) 0.99
HDL cholesterol (mmol/l) 1.1 (0.1) 1.2 (0.4) 0.72
LDL cholesterol (mmol/l) 2.4 (1.0) 2.2 (0.8) 0.64
Triglycerides (mmol/l) 1.7 (0.7) 1.5 (0.6) 0.77
Adiponectin (pg/ml) 1520 (461) 2833 (2773) 0.28
Leptin (pg/ml) 164 (99) 99 (72) 0.17
Estradiol (pmol/l) 97 (54) 115 (48) 0.92
PSA (ng/ml) 0.8 (0.5) 2.3 (4.9) 0.34
Testosterone (nmol/l) 6.7 (5.9) 14.2 (5.0) 0.036
Luteinizing hormone LH
(IU/l)
4.6 (2.6) 6.4 (3.5) 0.18
Follicle stimulating
hormone FSH (IU/l)
5.6 (4.7) 7.9 (5.3) 0.28
SHBG (nmol/l) 21.3 (6.9) 37.8 (19.6) 0.010
Haematocrit (%) 45.5 (3.4) 44.9 (2.1) 0.79
Haemoglobin (g/dl) 14.8 (1.3) 15.0 (1.0) 0.77
Free androgen index 28.3 (12.7) 37.9 (15.6) 0.14
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[11]. In another study reported by Francomano and col-
leagues, the metabolic effects of testosterone injections
were compared with dietary change and physical activity in
severely obese men with hypogonadism (n= 24) [20].
Following 1 year of testosterone injections combined with
improved lifestyle, there were signiﬁcant improvements in
HOMA-measures of insulin sensitivity, total cholesterol,
and inﬂammatory parameters [20].
The longer-term metabolic effects of TU IM therapy
(administered for up to 60-months) were reported by Traish
and Colleagues who performed an observational study on
255 (mainly elderly) men with sub-normal testosterone
levels [15]. Overall, there were improvements in parameters
of metabolic syndrome including lipid proﬁle and blood
pressure. In the subgroup with T2D (n= 81), there were
also signiﬁcant improvements in HbA1C, consistent with
our own data. In a further study by Haider and colleagues
on obese men with hypogonadism (n= 181; n= 72 with
T2D), long-acting intramuscular testosterone undecanoate
administered for up to 5-years resulted in signiﬁcant
improvements in waist circumference, BMI, lipid proﬁle
and glycaemic control [16]. A long-term study by Saad and
Colleagues on 411 obese and hypogonadal men who
received TU IM therapy for a maximum duration of 8-years,
and a mean follow-up of 6-years, demonstrated sustained
weight loss and reduced waist circumference [17]. Finally,
in a observational, prospective and cumulative registry of
656 hypogonadal men, including 360 hypogonadal men
who had received TU IM therapy for up to 10 years (the
remainder who had opted against TRT), signiﬁcantly
improved mortality (66–92%) related to CV disease was
shown in the treatment group [21].
Grillo and colleagues reported that testosterone resulted
in a rapid and dose-dependent increase of insulin release
from isolated pancreatic islets of Langerhans, in the presence
of non-stimulatory glucose concentrations [22]. A further
study on male mice lacking the androgen receptor in their
beta cells, demonstrated reduced glucose-stimulated insulin
secretion (GSIS) [23]. Dihydrotestosterone (DHT)-induced
enhancement of GSIS in cultured human islets is abolished
through treatment with an androgen receptor antagonist [23].
Interestingly, in both mouse and human islets, activation of
the glucagon-like peptide-1 receptor appeared to mediate the
insulinotropic effects of DHT [23]. A further rodent-based
study showed that gene expression within islets (including
genes implicated in insulin secretion and inﬂammation) is
altered with androgen receptor knock-out [24]. Observations
of deterioration of glycaemic control with androgen depri-
vation therapies for prostate cancer, combined with HOMA
%B analyses [25, 26] are consistent with the in vitro data
outlined above [23]. Data from other studies suggest that
gonadal steroids, including testosterone may inﬂuence
insulin secretion in a sex-speciﬁc manner [27].
Our own study demonstrated an improvement in HOMA
%B in those hypogonadal men with T2D following TU
therapy. We hypothesize that improvement in HOMA %B
in this subgroup is mediated, at least in part through direct
effects of testosterone on beta-cell insulin release, consistent
with observations by Grillo [22] and Navarro [23] as out-
lined above. Further studies are required to explore direct
effects of testosterone on beta-cell function, and the
potential therapeutic role of such a mechanism on improved
glycaemic control in hypogonadal men with T2D.
An important limitation of our study is that the numbers
included in each of the HG and EG groups is small. This
limits the power of our data, including for example the lipid
proﬁles, which need to be interpreted with care. Further-
more, given the well-established association between BMR
and lean body mass [28], it is possible that signiﬁcant
changes in BMR would have been discerned with a larger
cohort. A further limitation is the relatively short duration of
TU IM therapy between baseline and follow-up HMRU
studies (at least 6-months). In three of the HG subgroup
with T2D, glycaemic therapies were changed (on the basis
of clinical need) during therapy with TU IM therapy and
prior to their follow-up visit. The glycaemic effects of these
therapy changes have potential to confound the glycaemic
effects of TU IM therapy in this subgroup. Moreover, dif-
ferences in the duration of glycaemic therapies in subjects
with T2D in the HG group prior to their enrollment into the
study may have also inﬂuenced response to TU IM therapy.
Additionally, sleep studies were not repeated following
TRT. It has been reported previously that TRT is associated
Table 3 Comparison of glycaemic therapies at baseline and follow-up
assessments on the Human Metabolism Research Unit for the HG
subgroup with T2D
Subject
number
Glycaemic therapies
at baseline
Glycaemic therapies at follow-
up assessment
1 Lifestyle Unchanged
2 Metformin Unchanged
3 Metformin Unchanged
4 Metformin Addition of Levemir (12 units)
Liraglutide
5 Metformin Sitagliptin changed to
LiraglutideSitagliptin
6 Metformin Gliclazide and Liraglutide
changed to Lantus (20 units od)
and Canagliﬂozin
Pioglitazone
Gliclazide
Liraglutide
7 Metformin Unchanged
Liraglutide
Lantus
Novorapid
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with improved fatigue, energy, and vigor [29]. Future stu-
dies should assess the role of sleep improvement with TRT
as a potential mediator of this association. Our study was
also limited by the lack of a placebo arm and follow-up data
for the EG group, which has the potential to confound
follow-up metabolic data. However, although effects on
health-related behavior in the HG group are possible
through inclusion in this study, subjects were only required
to attend for one baseline and one follow-up metabolic
assessment, and otherwise received standard clinical care
and follow-up throughout the duration of the study.
In summary, we demonstrate, in a prospectively-designed
and highly-phenotyped study, evidence that TU IM therapy
improves glycaemic control and body composition in men
with obesity-related SH (including a subgroup with T2D),
the former mediated at least in part through improved beta-
cell function. The similar metabolic proﬁles between obese
HG and EG men should lower the threshold for screening
for hypogonadism in obese men. Longer-term placebo-
controlled randomized studies on the metabolic and cardio-
vascular effects of TU IM therapy in obese HG patients
(including those with T2D) are required, to gain mechanistic
insight, and to further inform clinicians of the utility, efﬁ-
cacy, and potential risks of such a treatment option.
Acknowledgements We acknowledge all the patients who contributed
towards the successful execution of this study. We acknowledge Bayer
for generously providing funding to support execution of this study.
We acknowledge Phillips Respironics for generously providing Alice
PDX portable sleep machines for use during this study. We
acknowledge Alison Campbell for her support in the execution of the
experiments within the Human Metabolism Research Unit.
Authors contribution All authors contributed towards preparation of
this manuscript.
Funding Funding generously provided by Bayer.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. S.A. Saboor Aftab, S. Kumar, T.M. Barber, The role of obesity
and type 2 diabetes mellitus in the development of male obesity-
associated secondary hypogonadism. Clin. Endocrinol. 78(3),
330–337 (2013)
2. D.M. Kelly, T.H. Jones, Testosterone and obesity. Obes. Rev. 16
(7), 581–606 (2015)
3. B. Calderon, J.M. Gomez-Martin, B. Vega-Pinero, A. Martin-
Hidalgo, J. Galindo, M. Luque-Ramirez et al. Prevalence of male
secondary hypogonadism in moderate to severe obesity and its
relationship with insulin resistance and excess body weight.
Andrology 4(1), 62–67 (2016)
4. J. Hofstra, S. Loves, B. van Wageningen, J. Ruinemans-Koerts, I.
Jansen, H. de Boer, High prevalence of hypogonadotropic hypo-
gonadism in men referred for obesity treatment. Neth. J. Med. 66
(3), 103–109 (2008)
5. L.M. Caronia, A.A. Dwyer, D. Hayden, F. Amati, N. Pitteloud, F.
J. Hayes, Abrupt decrease in serum testosterone levels after an
oral glucose load in men: implications for screening for hypogo-
nadism. Clin. Endocrinol. 78(2), 291–296 (2013)
6. H.E. Turner, J.A. Wass, Gonadal function in men with chronic
illness. Clin. Endocrinol. 47(4), 379–403 (1997)
7. P.M. Rao, D.M. Kelly, T.H. Jones, Testosterone and insulin
resistance in the metabolic syndrome and T2DM in men. Nat.
Rev. Endocrinol. 9(8), 479–493 (2013)
8. S. Dhindsa, H. Ghanim, M. Batra, N.D. Kuhadiya, S. Abuaysheh,
S. Sandhu et al. Insulin resistance and inﬂammation in hypogo-
nadotropic hypogonadism and their reduction after testosterone
replacement in men with type 2 diabetes. Diabetes Care 39(1),
82–91 (2016)
9. S. Kalinchenko, L.O. Vorslov, N.L. Aglamazian, L. Morgunov,
Efﬁcacy and safety of hormonal therapy with androgens (andro-
gel) in men with erectile dysfunction, partial androgen deﬁciency
of aging male and cardiovascular diseases. Urologiia 57(1), 9–61
(2007)
10. D.M. Kelly, S. Akhtar, D.J. Sellers, V. Muraleedharan, K.S.
Channer, T.H. Jones, Testosterone differentially regulates targets
of lipid and glucose metabolism in liver, muscle and adipose
tissues of the testicular feminised mouse. Endocrine 54(2),
504–515 (2016)
11. T.H. Jones, S. Arver, H.M. Behre, J. Buvat, E. Meuleman, I.
Moncada et al. Testosterone replacement in hypogonadal men
with type 2 diabetes and/or metabolic syndrome (the
TIMES2 study). Diabetes Care 34(4), 828–837 (2011)
12. N.L. Reddy, C. Peng, M.C. Carreira, L. Halder, J. Hattersley, M.
K. Piya et al. Enhanced thermic effect of food, postprandial NEFA
suppression and raised adiponectin in obese women who eat
slowly. Clin. Endocrinol. 82(6), 831–837 (2015)
13. D.A. Fields, M.I. Goran, M.A. McCrory, Body-composition
assessment via air-displacement plethysmography in adults and
children: a review. Am. J. Clin. Nutr. 75(3), 453–467 (2002)
14. J.B. Weir, New methods for calculating metabolic rate with spe-
cial reference to protein metabolism. J. Physiol. 109(1-2), 1–9
(1949)
15. A.M. Traish, A. Haider, G. Doros, F. Saad, Long-term testoster-
one therapy in hypogonadal men ameliorates elements of the
metabolic syndrome: an observational, long-term registry study.
Int. J. Clin. Pract. 68(3), 314–329 (2014)
16. A. Haider, F. Saad, G. Doros, L. Gooren, Hypogonadal obese men
with and without diabetes mellitus type 2 lose weight and show
improvement in cardiovascular risk factors when treated with
testosterone: an observational study. Obes. Res Clin. Pract. 8(4),
e339–e349 (2014)
17. F. Saad, A. Yassin, G. Doros, A. Haider, Effects of long-term
treatment with testosterone on weight and waist size in
411 hypogonadal men with obesity classes I-III: observational
data from two registry studies. Int. J. Obes. 40(1), 162–170
(2016)
18. D. Canoy, T.M. Barber, A. Pouta, A.L. Hartikainen, M.I.
McCarthy, S. Franks et al., Serum sex hormone-binding globulin
and testosterone in relation to cardiovascular disease risk factors in
Endocrine (2018) 60:175–184 183
young men: a population-based study. Eur. J. Endocrinol. 170(6),
863–872 (2014)
19. L.A. Cooper, S.T. Page, J.K. Amory, B.D. Anawalt, A.M. Mat-
sumoto, The association of obesity with sex hormone-binding
globulin is stronger than the association with ageing--implications
for the interpretation of total testosterone measurements. Clin.
Endocrinol. 83(6), 828–833 (2015)
20. D. Francomano, R. Bruzziches, G. Barbaro, A. Lenzi, A. Aversa,
Effects of testosterone undecanoate replacement and withdrawal
on cardio-metabolic, hormonal and body composition outcomes in
severely obese hypogonadal men: a pilot study. J. Endocrinol.
Invest. 37(4), 401–411 (2014)
21. A.M. Traish, A. Haider, K.S. Haider, G. Doros, F. Saad, Long-
term testosterone therapy improves cardiometabolic function and
reduces risk of cardiovascular disease in men with hypogonadism:
A real-life observational registry study setting comparing treated
and untreated (control) groups. J. Cardiovasc. Pharmacol. Ther. 22
(5), 414–433 (2017)
22. M.L. Grillo, A.P. Jacobus, R. Scalco, F. Amaral, D.O. Rodrigues,
E.S. Loss et al., Testosterone rapidly stimulates insulin release
from isolated pancreatic islets through a non-genomic dependent
mechanism. Horm. Metab. Res. 37(11), 662–665 (2005)
23. G. Navarro, W. Xu, D.A. Jacobson, B. Wicksteed, C. Allard, G.
Zhang et al., Extranuclear actions of the androgen receptor
enhance glucose-stimulated insulin secretion in the male. Cell
Metab. 23(5), 837–851 (2016)
24. W. Xu, T. Niu, B. Xu, G. Navarro, M.J. Schipma, F. Mauvais-
Jarvis, Androgen receptor-deﬁcient islet beta-cells exhibit altera-
tion in genetic markers of insulin secretion and inﬂammation. A
transcriptome analysis in the male mouse. J. Diabetes Complicat.
31(5), 787–795 (2017)
25. M. Inaba, Y. Otani, K. Nishimura, N. Takaha, A. Okuyama, M.
Koga et al. Marked hyperglycemia after androgen-deprivation
therapy for prostate cancer and usefulness of pioglitazone for its
treatment. Metabolism 54(1), 55–59 (2005)
26. F. Mauvais-Jarvis, Androgen-deprivation therapy and pancreatic
beta-cell dysfunction in men. J. Diabetes Complicat. 30(3),
389–390 (2016)
27. F. Mauvais-Jarvis, Role of sex steroids in beta cell function,
growth, and survival. Trends Endocrinol. Metab. 27(12), 844–855
(2016)
28. D. Halliday, R. Hesp, S.F. Stalley, P. Warwick, D.G. Altman, J.S.
Garrow, Resting metabolic rate, weight, surface area and body
composition in obese women. Int. J. Obes. 3(1), 1–6 (1979)
29. A.M. Traish, Testosterone and weight loss: the evidence. Curr.
Opin. Endocrinol. Diabetes Obes. 21(5), 313–322 (2014)
184 Endocrine (2018) 60:175–184
